Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy. Otsuka is hoping to file for approval of its ...

The FDA approved Novartis' Vanrafia® (atrasentan), a selective endothelin A receptor antagonist, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Patients requiring treatment for proteinuria reduction in primary immunoglobulin A (IgA) nephropathy now have a solution, with the FDA's accelerated approval of atrasentan (Vanrafia; Novartis)..

"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat patients with the rare kidney disease immunoglobulin A nephropathy ...

"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

“Today’s approval marks an important milestone for people living with IgA nephropathy ... According to Novartis, eGFR data are expected to be announced in 2026. Vanrafia is supplied as ...

(Image Credits: Pixabay) Novartis on Thursday announced the ... approval marks an important milestone for people living with IgA nephropathy, offering a new option that can be seamlessly ...